Should You Buy This Stock After a Regulatory Setback?
The past two-and-a-half years have been rough for Moderna (NASDAQ: MRNA). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche to shrink started selling off the stock in early 2022. The vaccine maker's shares are down by 43% since then.
Moderna isn't resting on its laurels, though. The company is developing several exciting candidates. Unfortunately, the most advanced of the bunch recently ran into a regulatory setback. Let's look deeper into that recent news and what it could mean for investors.
Source Fool.com
Moderna Inc. Stock
€107.88
0.500%
With 31 Buy predictions and 2 Sell predictions Moderna Inc. is one of the favorites of our community.
As a result the target price of 130 € shows a positive potential of 20.5% compared to the current price of 107.88 € for Moderna Inc..
